| ¿µ¹® | oral administration | ÇÑ±Û | °æ±¸º¹¿ë |
|---|---|---|---|
| ¼³¸í | ¾àÀ» Åõ¿©ÇÏ´Â ¹æ¹ý¿¡´Â ¿©·¯ °¡Áö°¡ ÀÖ´Ù. Å©°Ô ³ª´©¾î º¸¸é, ÀÔÀ» °ÅÃÄ À§Ã¢Àڰ踦 ÅëÇØ ³Ö´Â ¹æ¹ý°ú À§Ã¢Àڰ踦 ÅëÇÏÁö ¾Ê°í ¹Ù·Î Ç÷¾×À¸·Î ³Ö´Â ¹æ¹ýÀÌ ÀÖ´Ù. À§Ã¢Àڰ踦 ÅëÇÏÁö ¾Ê´Â ¹æ¹ýÀ¸·Î °¡Àå ÈçÇÑ ¹æ¹ýÀº Áֻ縦 ÀÌ¿ëÇÏ´Â ¹æ¹ýÀÌ´Ù. ÇÏÁö¸¸, À̿ܿ¡ Ç×¹®À» ÅëÇØ ³Ö´Â Á¾à½Ä¹æ¹ý°ú Çô¹Ø¿¡ ³Ö´Â Çô¹ØÅõ¿©¹ýµµ ÀÖ´Ù. ±×·¯³ª ´ëºÎºÐÀÇ ¾àÁ¦´Â °æ±¸º¹¿ëÀ» ÇÏ°Ô µÈ´Ù. °æ±¸º¹¿ë¿¡ ´ëÇÑ ¾àÀÚ´Â p.o.(per oral)·Î Ç¥±âÇÑ´Ù. °æ±¸º¹¿ëÁ¦ÀÇ ´ÜÁ¡Àº º¹¿ëÇÑ ¾àÁ¦°¡ À§Ã¢ÀÚ°ü°è¸¦ °ÅÄ¡¸é¼ »ç¶÷¸¶´Ù °¢±â ´Ù¸¥ Èí¼öÁ¤µµ¿Í ´ë»çÁ¤µµ¸¦ °ÅÄ¡°Ô µÇ¹Ç·Î ÀÏÁ¤ÇÑ ³óµµÀ¯Áö°¡ ¾î·Æ´Ù´Âµ¥ ÀÖ´Ù. ¶ÇÇÑ °æ±¸º¹¿ëÁ¦ÀÇ ¸ð¾çÀÌ Ä¸½¶ÇüÀÎÁö, ȤÀº °¡·çÇüÀÎÁö¿¡ µû¶ó¼µµ °°Àº ¾àÀÌÁö¸¸, ¼·Î ´Ù¸¥ È¿°ú¸¦ ³ªÅ¸³¾ ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | oral cavity | ÇÑ±Û | ±¸° |
|---|---|---|---|
| ¼³¸í | ÀÔÀ» ¹ú¿©¼ ÀÔ¼Ó¿¡¼ º¼ ¼ö ÀÖ´Â °ø°£À¸·Î ÀÔõÀå, Æíµµ, ¸ñÁ¥À» º¼ ¼ö ÀÖ´Ù. ![]() |
||
| ¿µ¹® | oral cavity | ÇÑ±Û | ÀÔ¾È |
|---|---|---|---|
| ¼³¸í | ÀÔÀ» ¹ú¿©¼ ÀÔ¼Ó¿¡¼ º¼ ¼ö ÀÖ´Â °ø°£À¸·Î ÀÔõÀå, Æíµµ, ¸ñÁ¥À» º¼ ¼ö ÀÖ´Ù. |
||
| ORS | olfactory reference syndrome; oral rehydration solution; oral surgery, oral surgeon; Orthopaedic Res... |
|---|---|
| HCL | hairy-cell leukemia; human cultured lymphoblasts |
| HCl | hydrogen chloride |
| MDIPT | Multicenter Diltiazem Postinfarction Trial |
| PREDICT | Prospective Randomized Evaluation of Diltiazem CD Trial |
| D | Diltiazem |
|---|---|
| DIL | Diltiazem |
| DTZ | Diltiazem |
| DZ | Diltiazem |
| Apo | Apomorphine HCl |
naso-oral
| diltiazem | <chemical> A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of the calcium ion in membrane functions. It is also teratogenic. Pharmacological action: antihypertensive agents, calcium channel blockers, cardiovascular agents, teratogens, vasodilator agents. Direct, potent negative chronotrope with only mild negative inotropic effect; slows conduction in AV node; coronary vasodilation with less systemic vasodilation than verpamil. Chemical name: 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- Uses: Control ventricular response with atrial fibrillation Dose: 0.25 mg/kg IV over 2 minutes May repeat at 0.35 mg/kg after 15 minutes. Maintenance infusion at 5 - 15 mg/hr. Potential complications: Less hypotension than with verapamil since less vasodilation and myocardial depression; bradycardia; may exacerbate AV block; synergistic interaction with beta blockers; relatively contraindicated with congestive heart failure. Note: Diltiazem can accelerate heart rate and decrease blood pressure, especially in patients with Wolff-Parkinson-White or wide-complex tachycardia. (15 Mar 2000) |
|---|---|
| diltiazem hydrochloride | 1,5-Benzothiazepin-4(5H)one,3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-monohydrochloride, (+)-cis-;a calcium channel blocking agent used as a coronary vasodilator and antihypertensive. (05 Mar 2000) |
| administration, oral | The giving of drugs, chemicals, or other substances by mouth. (12 Dec 1998) |
| cancer, oral | Cancer of the mouth area. A sore in the mouth that does not heal can be a warning sign of oral cancer. A biopsy is the only to know whether as abnormal area in the oral cavity is cancer. Oral cancer is caused by tobacco (smoking and chewing) and alcohol use. Surgery to remove the tumour in the mouth is the usual treatment for patients with oral cancer. (12 Dec 1998) |
| candidiasis, oral | Infection of the mucous membranes of the mouth by a fungus of the genus candida. (12 Dec 1998) |
| canine oral papilloma | Warts affecting mucous membranes of young dogs; caused by a papillomavirus. (05 Mar 2000) |
| magnesia and alumina oral suspension | A mixture of magnesium hydroxide and variable amounts of aluminum oxide; used as an antacid. (05 Mar 2000) |
| pathology, oral | A dental specialty concerned with pathology of the oral cavity. (12 Dec 1998) |
| pharyngo-oral | Relating to the pharynx and the mouth; oropharyngeal. Origin: pharyngo-+ L. Os (or-), mouth (05 Mar 2000) |
| combination oral contraceptive | A mixture of a steroid having progestational activity and an oestrogen. (05 Mar 2000) |
| contraceptives, oral | Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are generally oestrogen or progesterone or both. (12 Dec 1998) |
| contraceptives, oral, combined | Fixed drug combinations administered orally for contraceptive purposes. (12 Dec 1998) |
| contraceptives, oral, hormonal | Oral contraceptives which owe their effectiveness to hormonal preparations. (12 Dec 1998) |
| contraceptives, oral, sequential | Drugs administered orally and sequentially for contraceptive purposes. (12 Dec 1998) |
| contraceptives, oral, synthetic | Oral contraceptives which owe their effectiveness to synthetic preparations. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|